Channelopathies, painful neuropathy, and diabetes: Which way does the causal arrow point?

Trends in Molecular Medicine

Volumn 20, Issue 10, 2014, Pages 544-550

  Hoeijmakers, Janneke G J ^a   Faber, Catharina G ^a   Merkies, Ingemar S J ^a,b   Waxman, Stephen G ^c,d  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Infection and Immunology   (Netherlands)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Diabetes mellitus; Diabetic neuropathy; NaV1.7; Painful neuropathy; Sodium channelopathy; cells

Indexed keywords

SODIUM CHANNEL NAV1.7; VOLTAGE GATED SODIUM CHANNEL; SCN9A PROTEIN, HUMAN;

CHANNELOPATHY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DISEASE PREDISPOSITION; HUMAN; MUTATION; NERVE CELL LESION; NEUROPATHY; NOTE; PAINFUL NEUROPATHY; PANCREAS ISLET BETA CELL; PANCREAS ISLET DISEASE; PANCREATIC ISLET CELL DYSFUNCTION; PERIPHERAL NEUROPATHY; SPINAL CORD NERVE CELL; SPINAL GANGLION; CHANNELOPATHIES; DIABETIC NEUROPATHIES; GENETIC PREDISPOSITION; GENETICS; METABOLISM; PAIN; PATHOLOGY; PERIPHERAL NERVOUS SYSTEM DISEASES;

CHANNELOPATHIES; DIABETIC NEUROPATHIES; GANGLIA, SPINAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INSULIN-SECRETING CELLS; MUTATION; NAV1.7 VOLTAGE-GATED SODIUM CHANNEL; PAIN; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 84921998193     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2014.06.003     Document Type: Review

References (81)

1. Boulton A.J., et al. Diabetic somatic neuropathies. Diabetes Care 2004, 27:1458-1486.
2. Tesfaye S., et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010, 33:2285-2293.
3. Abbott C.A., et al. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care 2011, 34:2220-2224.
4. Sima A.A., Kamiya H. Diabetic neuropathy differs in type 1 and type 2 diabetes. Ann. N. Y. Acad. Sci. 2006, 1084:235-249.
5. Callaghan B.C., et al. Diabetic neuropathy: one disease or two?. Curr. Opin. Neurol. 2012, 25:536-541.
6. Callaghan B.C., et al. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012, 11:521-534.
7. Davies M., et al. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006, 29:1518-1522.
8. Spallone V., Greco C. Painful and painless diabetic neuropathy: one disease or two?. Curr. Diab. Rep. 2013, 13:533-549.
9. Van Acker K., et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab. 2009, 35:206-213.
10. Guariguata L., et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diab. Res. Clin. Pract. 2014, 103:137-149.
11. Gore M., et al. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J. Pain Symptom Manage. 2005, 30:374-385.
12. Sadosky A., et al. Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: results from a retrospective chart review and cross-sectional survey. Diabetes Metab. Syndr. Obes. 2013, 6:79-92.
13. Schaefer C., et al. Health status, function, productivity, and costs among individuals with idiopathic painful peripheral neuropathy with small fiber involvement in the United States: results from a retrospective chart review and cross-sectional survey. J. Med. Econ. 2014, 17:394-407.
14. DiBonaventura M.D., et al. Association between pain severity and health care resource use, health status, productivity and related costs in painful diabetic peripheral neuropathy patients. Pain Med. 2011, 12:799-807.
15. Ritzwoller D.P., et al. Comorbidities, healthcare service utilization and costs for patients identified with painful DPN in a managed-care setting. Curr. Med. Res. Opin. 2009, 25:1319-1328.
16. Jensen T.S., et al. A new definition of neuropathic pain. Pain 2011, 152:2204-2205.
17. Tesfaye S., et al. Mechanisms and management of diabetic painful distal symmetrical polyneuropathy. Diabetes Care 2013, 36:2456-2465.
18. Malik R., et al. Small fiber neuropathy: role in the diagnosis of diabetic sensorimotor polyneuropathy. Diabetes Metab. Res. Rev. 2011, 27:678-684.
19. Sorensen L., et al. The relationship among pain, sensory loss, and small nerve fibers in diabetes. Diabetes Care 2006, 29:883-887.
20. Gandhi R.A., et al. Painful diabetic neuropathy is associated with greater autonomic dysfunction than painless diabetic neuropathy. Diabetes Care 2010, 33:1585-1590.
21. Smith A.G. Impaired glucose tolerance and metabolic syndrome in idiopathic neuropathy. J. Peripher. Nerv. Syst. 2012, 17(Suppl. 2):15-21.
22. Smith A.G., et al. Epidermal nerve innervation in impaired glucose tolerance and diabetes-associated neuropathy. Neurology 2001, 57:1701-1704.
23. Smith A.G., Singleton J.R. Impaired glucose tolerance and neuropathy. Neurologist 2008, 14:23-29.
24. Papanas N., Ziegler D. Prediabetic neuropathy: does it exist?. Curr. Diab. Rep. 2012, 12:376-383.
25. Waxman S.G. The neuron as a dynamic electrogenic machine: modulation of sodium-channel expression as a basis for functional plasticity in neurons. Philos. Trans. R. Soc. Lond. B 2000, 355:199-213.
26. Catterall W.A., et al. International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol. Rev. 2005, 57:411-425.
27. Hong S., et al. Early painful diabetic neuropathy is associated with differential changes in tetrodotoxin-sensitive and -resistant sodium channels in dorsal root ganglion neurons in the rat. J. Biol. Chem. 2004, 279:29341-29350.
28. Sun W., et al. Reduced conduction failure of the main axon of polymodal nociceptive C-fibres contributes to painful diabetic neuropathy in rats. Brain 2012, 135:359-375.
29. Galloway C., Chattopadhyay M. Increases in inflammatory mediators in DRG implicate in the pathogenesis of painful neuropathy in type 2 diabetes. Cytokine 2013, 63:1-5.
30. Craner M.J., et al. Changes of sodium channel expression in experimental painful diabetic neuropathy. Ann. Neurol. 2002, 52:786-792.
31. Cummins T.R., et al. Slow closed-state inactivation: a novel mechanism underlying ramp currents in cells expressing the hNE/PN1 sodium channel. J. Neurosci. 1998, 18:9607-9619.
32. Waxman S.G. Neurobiology: a channel sets the gain on pain. Nature 2006, 444:831-832.
33. Dib-Hajj S.D., et al. The Na(V)1.7 sodium channel: from molecule to man. Nat. Rev. Neurosci. 2013, 14:49-62.
34. Chattopadhyay M., et al. Reduction of voltage gated sodium channel protein in DRG by vector mediated miRNA reduces pain in rats with painful diabetic neuropathy. Mol. Pain 2012, 8:17.
35. Chattopadhyay M., et al. Vector-mediated release of GABA attenuates pain-related behaviors and reduces Na(V)1.7 in DRG neurons. Eur. J. Pain 2011, 15:913-920.
36. Zhang J.L., et al. Gabapentin reduces allodynia and hyperalgesia in painful diabetic neuropathy rats by decreasing expression level of Nav1.7 and p-ERK1/2 in DRG neurons. Brain Res. 2013, 1493:13-18.
37. Bierhaus A., et al. Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat. Med. 2012, 18:926-933.
38. Mert T., Gunes Y. Antinociceptive activities of lidocaine and the nav1.8 blocker a803467 in diabetic rats. J. Am. Assoc. Lab. Anim. Sci. 2012, 51:579-585.
39. Renganathan M., et al. Contribution of Na(v)1.8 sodium channels to action potential electrogenesis in DRG neurons. J. Neurophysiol. 2001, 86:629-640.
40. Rush A.M., et al. Multiple sodium channels and their roles in electrogenesis within dorsal root ganglion neurons. J. Physiol. 2007, 579:1-14.
41. Black J.A., et al. Multiple sodium channel isoforms and mitogen-activated protein kinases are present in painful human neuromas. Ann. Neurol. 2008, 64:644-653.
42. Dib-Hajj S.D., et al. Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces bursting of sensory neurons. Brain 2005, 128:1847-1854.
43. Fertleman C.R., et al. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron 2006, 52:767-774.
44. Cox J.J., et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature 2006, 444:894-898.
45. Faber C.G., et al. Gain of function Nanu1.7 mutations in idiopathic small fiber neuropathy. Ann. Neurol. 2012, 71:26-39.
46. Faber C.G., et al. Gain-of-function Nav1.8 mutations in painful neuropathy. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:19444-19449.
47. Huang J., et al. Gain-of-function mutations in sodium channel NaV1.9 in painful neuropathy. Brain 2014, 137:1627-1642.
48. Brunetti A., et al. Recent advances in the molecular genetics of type 2 diabetes mellitus. World J. Diabetes 2014, 5:128-140.
49. Ounissi-Benkalha H., Polychronakos C. The molecular genetics of type 1 diabetes: new genes and emerging mechanisms. Trends Mol. Med. 2008, 14:268-275.
50. Rorsman P., Braun M. Regulation of insulin secretion in human pancreatic islets. Annu. Rev. Physiol. 2013, 75:155-179.
51. Ahn H.S., et al. Differential effect of D623N variant and wild-type Na(v)1.7 sodium channels on resting potential and interspike membrane potential of dorsal root ganglion neurons. Brain Res. 2013, 1529:165-177.
52. Han C., et al. Nav1.7-related small fiber neuropathy: impaired slow-inactivation and DRG neuron hyperexcitability. Neurology 2012, 78:1635-1643.
53. Han C., et al. Functional profiles of SCN9A variants in dorsal root ganglion neurons and superior cervical ganglion neurons correlate with autonomic symptoms in small fibre neuropathy. Brain 2012, 135:2613-2628.
54. Rush A.M., et al. A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:8245-8250.
55. Braun M., et al. Voltage-gated ion channels in human pancreatic beta-cells: electrophysiological characterization and role in insulin secretion. Diabetes 2008, 57:1618-1628.
56. Hiriart M., Aguilar-Bryan L. Channel regulation of glucose sensing in the pancreatic beta-cell. Am. J. Physiol. Endocrinol. Metab. 2008, 295:E1298-E1306.
57. Fridlyand L.E., et al. Ion channels and regulation of insulin secretion in human beta-cells: a computational systems analysis. Islets 2013, 5:1-15.
58. Vignali S., et al. Characterization of voltage-dependent sodium and calcium channels in mouse pancreatic A- and B-cells. J. Physiol. 2006, 572:691-706.
59. Ernst S.J., et al. Sodium channel beta1 regulatory subunit deficiency reduces pancreatic islet glucose-stimulated insulin and glucagon secretion. Endocrinology 2009, 150:1132-1139.
60. Muoio D.M., Newgard C.B. Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat. Rev. Mol. Cell Biol. 2008, 9:193-205.
61. Ashcroft F.M., Rorsman P. Electrophysiology of the pancreatic beta-cell. Prog. Biophys. Mol. Biol. 1989, 54:87-143.
62. Girard C.A., et al. Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes. J. Clin. Invest. 2009, 119:80-90.
63. Clark R.H., et al. Muscle dysfunction caused by a KATP channel mutation in neonatal diabetes is neuronal in origin. Science 2010, 329:458-461.
64. Meissner H.P., Schmelz H. Membrane potential of beta-cells in pancreatic islets. Pflugers Arch. 1974, 351:195-206.
65. Plant T.D. Na+ currents in cultured mouse pancreatic B-cells. Pflugers Arch. 1988, 411:429-435.
66. Rorsman P., et al. Electrophysiology of pancreatic beta-cells in intact mouse islets of Langerhans. Prog. Biophys. Mol. Biol. 2011, 107:224-235.
67. Pressel D.M., Misler S. Sodium channels contribute to action potential generation in canine and human pancreatic islet B cells. J. Membr. Biol. 1990, 116:273-280.
68. Barnett D.W., et al. Voltage-dependent Na+ and Ca2+ currents in human pancreatic islet beta-cells: evidence for roles in the generation of action potentials and insulin secretion. Pflugers Arch. 1995, 431:272-282.
69. Meyer-Hermann M.E. The electrophysiology of the beta-cell based on single transmembrane protein characteristics. Biophys. J. 2007, 93:2952-2968.
70. Kizer J.S., et al. The in vitro inhibition of insulin secretion by diphenylhydantoin. J. Clin. Invest. 1970, 49:1942-1948.
71. Tamburrano S., et al. Studies on the hyperglycemic effect of diphenylhydantoin in normal golden hamsters. Horm. Metab. Res. 1976, (Suppl. 6):74-79.
72. Qi H., Newman G.C. Phenytoin-induced hyperglycaemia may confound rat cerebroprotection models. Clin. Exp. Pharmacol. Physiol. 1996, 23:893-897.
73. Carter B.L., et al. Phenytoin-induced hyperglycemia. Am. J. Hosp. Pharm. 1981, 38:1508-1512.
74. Klein J.P. Diphenylhydantoin intoxication associated with hyperglycemia. J. Pediatr. 1966, 69:463-465.
75. Peters B.H., Samaan N.A. Hyperglycemia with relative hypoinsulinemia in diphenylhydantoin toxicity. N. Engl. J. Med. 1969, 281:91-92.
76. Treasure T., Toseland P.A. Hyperglycaemia due to phenytoin toxicity. Arch. Dis. Child. 1971, 46:563-564.
77. Perry-Keene D.A., et al. The effect of long-term diphenylhydantoin therapy on glucose tolerance and insulin secretion: a controlled trial. Clin. Endocrinol. 1980, 12:575-580.
78. Tannhauser M., et al. Carbamazepine-induced hyperglycemia in hyponatremic rats. Pharmacology 1982, 24:123-125.
79. Persson A.K., et al. Neuropathy-associated Nav1.7 variant I228M impairs integrity of dorsal root ganglion neuron axons. Ann. Neurol. 2013, 73:140-145.
80. Persson A.K., et al. Sodium channels contribute to degeneration of dorsal root ganglion neurites induced by mitochondrial dysfunction in an in vitro model of axonal injury. J. Neurosci. 2013, 33:19250-19261.
81. Waxman S.G., et al. Probability of conduction deficit as related to fiber length in random-distribution models of peripheral neuropathies. J. Neurol. Sci. 1976, 29:39-53.